Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries).
about
Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of MexicoVaccines for preventing rotavirus diarrhoea: vaccines in useVaccines for preventing rotavirus diarrhoea: vaccines in useVaccines for preventing rotavirus diarrhoea: vaccines in usePerformance of rotavirus vaccines in developed and developing countriesHisto-blood group antigens as receptors for rotavirus, new understanding on rotavirus epidemiology and vaccine strategy.Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5)Hospitalisation for rotavirus gastroenteritis in the paediatric population in the Veneto Region, Italy.A multi-center, qualitative assessment of pediatrician and maternal perspectives on rotavirus vaccines and the detection of Porcine circovirus.Prevention of rotavirus gastroenteritis in infants and children: rotavirus vaccine safety, efficacy, and potential impact of vaccines.Hospital bed occupancy for rotavirus and all cause acute gastroenteritis in two Finnish hospitals before and after the implementation of the national rotavirus vaccination program with RotaTeq®Heterogeneity of rotavirus testing and admitting practices for gastroenteritis among 12 tertiary care pediatric hospitals: Implications for surveillance.Human rotavirus group a serotypes causing gastroenteritis in children less than 5 years and HIV-infected adults in Viwandani slum, NairobiProjecting the effectiveness of RotaTeq® against rotavirus-related hospitalizations and deaths in six Asian countriesEfficacy, safety and effectiveness of licensed rotavirus vaccines: a systematic review and meta-analysis for Latin America and the Caribbean.Laboratory-Confirmed Rotavirus Disease in Utah Children: Clinical and Economic Impact of Rotavirus Vaccination.Impact of rotavirus vaccination in regions with low and moderate vaccine uptake in Germany.Community management of acute malnutrition in the developing worldIssues in pediatric vaccine-preventable diseases in low- to middle-income countriesRotaTeq: a three-dose oral pentavalent reassortant rotavirus vaccine.Update on Rotarix: an oral human rotavirus vaccine.Correlates of protection against human rotavirus disease and the factors influencing protection in low-income settings.Effect of monovalent rotavirus vaccine on rotavirus disease burden and circulating rotavirus strains among children in Morocco.Diversity of rotavirus strains circulating in children under 5 years of age admitted to hospital for acute gastroenteritis in Morocco, June 2006 to May 2009.Clinical trials: The mathematics of falling vaccine efficacy with rising disease incidence.Modeling seasonal variation in rotavirus hospitalizations for use in evaluating the effect of rotavirus vaccine.Multiplexed one-step RT-PCR VP7 and VP4 genotyping assays for rotaviruses using updated primers.Using a monitoring and evaluation framework to improve study efficiency and quality during a prospective cohort study in infants receiving rotavirus vaccination in El Alto, Bolivia: the Infant Nutrition, Inflammation, and Diarrheal Illness (NIDI) stThe use of an adequate mathematical model is crucial to evaluate vaccine effectiveness.6th World Congress of the World Society for Pediatric Infectious Diseases (WSPID)
P2860
Q21261530-19DAB448-4EF8-4698-8391-EF39EBC1810CQ24197495-A5EBCCF8-748D-4215-A0B7-EBF61CC63373Q24203645-BA599999-BC1F-4E88-82CD-BADB59514BF9Q24235411-D9775CD4-DA56-4B47-8E78-921514200DBBQ24600612-5B8AE911-05CA-4520-B19F-3072F8DC85EEQ30234848-6E093C08-944E-458F-9C65-D6688093C079Q33601981-ABADD5AD-F9F1-401B-A52A-684AAF3FC15AQ33726130-AC3B86BA-8762-49AE-BE06-9A2010684DAEQ34029254-E63C078F-5855-44E2-9DF4-488D383D7AFCQ34064371-24A2F6E8-87C0-49CD-8534-972B5B3746F1Q34706627-4AF0A3AF-E193-4B11-A9FC-B7F1FCD407F5Q34789779-8509219D-4358-4100-9FE3-2A47A68451CBQ35109584-BE2849CF-C8BE-42EA-BACD-455973E6ABB4Q35194876-BCAF3DC8-700D-4CB7-885B-6F360EE230FEQ36249319-03C1F865-45EB-4C48-AE1C-EFCF622B3091Q36851125-A28C3898-CC72-445F-909C-8736BF6208A5Q36864913-46C7C09C-F50E-4E0A-987E-C20DFB90C429Q37101530-2B779F23-AA1F-4969-A897-EDFC18F6BCDFQ37264972-DFBFB31C-4AC2-4F96-AED2-D4BC3AA1C0FCQ37340449-093D9F64-E02F-4FB2-A4C3-14BDC79115D2Q37640107-DD64281F-5001-40CE-A230-ABA1B51DCAE9Q38281298-47F1F50E-2716-420E-A3B0-7E5DF0A7E697Q38903517-EDF0A8C9-5EC3-4499-82F9-46D565876F6DQ38903522-BDC7EF2B-9CB2-4C0A-A21C-661BA3B5B42BQ39027310-33925937-050B-45EB-8AA7-D9353A5566C0Q39432918-E326280C-68D0-4BE7-953B-1315F8A4ECA4Q41078001-62596377-6B17-4CA9-9EF1-98F336531BA4Q47153877-20FE93F0-E9C7-43B3-8654-144B20283F58Q51338282-FA071C97-0BE0-4999-9EFC-8FC966C19226Q57108439-90B11B7A-483F-42A0-B256-7C7D16337A37
P2860
Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries).
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Efficacy of a pentavalent rota ...... three regions (11 countries).
@en
Efficacy of a pentavalent rota ...... ilization across three regions
@nl
type
label
Efficacy of a pentavalent rota ...... three regions (11 countries).
@en
Efficacy of a pentavalent rota ...... ilization across three regions
@nl
prefLabel
Efficacy of a pentavalent rota ...... three regions (11 countries).
@en
Efficacy of a pentavalent rota ...... ilization across three regions
@nl
P2093
P1476
Efficacy of a pentavalent rota ...... three regions (11 countries).
@en
P2093
Celia D C Christie
David O Matson
John R Cook
Michele Coia
Penny Heaton
Robbin Itzler
Timo Vesikari
P304
P356
10.1016/S1201-9712(07)60019-8
P478
11 Suppl 2
P577
2007-11-01T00:00:00Z